论文部分内容阅读
目的观察复方苦参注射液联合放化疗治疗晚期头颈部鳞癌患者的近期疗效、生活质量、化疗毒副反应及疼痛缓解情况。方法选择我科2007年1月—2011年1月无法手术的晚期头颈部鳞癌患者76例,随机分为观察组40例(复方苦参注射液联合放化疗)和对照组36例(单纯放化疗),分别观察二组近期疗效(RECIST标准)、生活质量(Karnofsky评分),毒副反应(WHO抗癌药急性和亚急性毒性反应表现与分度标准)和疼痛缓解情况(NRS法)的差异。结果观察组总缓解率(CR+PR)为70.0%,对照组总缓解率为66.7%,二组差异无统计学意义(P>0.05),二组KPS评分改善者分别为18例和7例(P<0.05),二组间不良反应差异无统计学意义(P>0.05),二组疼痛缓解者分别为32例和19例(P<0.05)。结论复方苦参注射液虽未能提高放化疗疗效,但可以改善临床症状,提高生活质量。
Objective To observe the short-term curative effect, quality of life, side effects of chemotherapy and pain relief in patients with advanced head and neck squamous cell carcinoma treated by compound kushen injection and chemoradiotherapy. Methods 76 patients with advanced head and neck squamous cell carcinoma who were inoperable in our department from January 2007 to January 2011 were randomly divided into observation group (40 cases), compound matrine injection combined with chemoradiation (36 cases) and control group (RECIST standard), quality of life (Karnofsky score), toxic and side effects (WHO anticancer drugs acute and subacute toxicity performance standards and indexing) and pain relief (NRS) The difference. Results The total remission rate (CR + PR) was 70.0% in the observation group and 66.7% in the control group, with no significant difference between the two groups (P> 0.05). The improvement rate of KPS in the two groups was 18 cases and 7 cases (P <0.05). There was no significant difference in adverse reactions between the two groups (P> 0.05). The pain relievers in the two groups were 32 and 19 (P <0.05) respectively. Conclusion Compound Kushen injection although not improve the efficacy of radiotherapy and chemotherapy, but can improve clinical symptoms and improve quality of life.